ALUNBRIG(TM) BRIGATINIB 39 mg TABLETS

ALUNBRIG® is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

 

In the News

Learn more about the FDA approval of ALUNBRIG.

View Press Release

Patient Support

ALUNBRIG 1Point can support your patients throughout the course of their therapy.

  • Access: A Patient Access Specialist can work with your patient and your office to conduct a benefits investigation and provide you both with details on your patient's drug coverage and options
  • Afford: Regardless of your patients' insurance status, ALUNBRIG 1Point can help identify an array of financial assistance programs for which they may be eligible
  • Assist: ALUNBRIG 1Point is committed to supporting your patients throughout their treatment by offering a wide range of services to get them the information they need, and assist with day-to-day concerns associated with their treatment
Find Out More

Important Resources for Your Practice

Download Dosing Guide

Stay Connected

Stay informed about ALUNBRIG—sign up to be notified about product and news updates.

Required fields*

Please enter your first name.
Please enter your last name.
Please enter your email.
Please select your specialty.
Submit

You Have Successfully Registered

Thank you for registering. You will hear from us when we have updates.

ALUNBRIG: Product Information


Please read full Prescribing Information for ALUNBRIG.

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib).

This link will take you to the corporate Takeda Oncology website.

Continue Cancel

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib).

This link will take you to the ALUNBRIG 1Point website.

Continue Cancel

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib).

This link will take you to the FDA website.

Continue Cancel

The site you are about to enter is intended for US healthcare professionals only.

Please confirm that you are a US healthcare professional.

Yes, I confirm that I am a US healthcare professional Cancel